Table 3.
Tumor somatic variants and their association with overall survival in BTC
| Mutation | Frequency (%) | HR | Median OS (Mos.) | FDR |
|---|---|---|---|---|
| ARID1A(+) | 25(13.66%) | 0.937 | 39.59 | 0.9532 |
| ARID1A(−) | 158(86.34%) | . | 37.65 | . |
| CDKN2A (+) | 53(28.96%) | 1.117 | 49.15 | 0.9058 |
| CDKN2A (−) | 130(71.04%) | . | 39.59 | . |
| FGFR2(+) | 23(12.57%) | 0.141 | Not reached | 0.0067 |
| FGFR2(−) | 160(87.43%) | . | 34.76 | . |
| IDH1(+) | 24(13.11%) | 0.665 | 39.59 | 0.6162 |
| IDH1(−) | 159(86.89%) | . | 34.76 | . |
| KRAS(+) | 41(22.40%) | 1.673 | 19.65 | 0.1364 |
| KRAS(−) | 142(77.60%) | . | 45.96 | . |
| PBRM1(+) | 19(10.38%) | 1.003 | Not reached | 0.9935 |
| PBRM1(−) | 164(89.62%) | . | 39.59 | . |
| PIK3CA(+) | 20(10.93%) | 0.684 | 42.58 | 0.7401 |
| PIK3CA(−) | 163(89.07%) | . | 37.65 | . |
| SMAD4(+) | 19(10.38%) | 1.163 | 49.15 | 0.9058 |
| SMAD4(−) | 164(89.62%) | . | 39.59 | . |
| TP53(+) | 51(27.87%) | 2.625 | 19.29 | 0.0003 |
| TP53(−) | 132(72.13%) | . | 67.12 | . |
Genes with an incidence > 10% of all patients with were assessed for their association with overall survival. (+) indicates the presence of a mutation in the listed gene.